Methods of using muscarinic antagonists in the treatment of depression

US12396988B2 · kind B2 · utility

Assignees

• The Board of Regents of the University of Texas System · US
• UNIVERSITY OF MARYLAND, BALTIMORE · US
• THE MCLEAN HOSPITAL CORPORATION · US
• THE REGENTS OF THE UNIVERSITY OF MICHIGAN · US

Inventors

• Andrew Coop · Columbia, US
• Chad R. Johnson · Baltimore, US
• Jack Bergman · Cambridge, US
• Brian D. Kangas · Boston, US
• James H. Woods · Ann Arbor, US
• Emily M. Jutkiewicz · Dexter, US
• Gail Winger · Ann Arbor, US

Key dates

• Filing date: Apr 6, 2020
• Grant date: Aug 26, 2025
• Expiry date: Sep 8, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Muscarinic antagonist are provided that are used in the treatment of depression in a subject, such as humans. The muscarinic antagonist of the invention can relieve depression without effecting cognitive functions in the treated subject.